Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
6.5 EUR
91.37 M EUR
781.94 M EUR
3.69 M
About YPSOMED HLDG
Sector
Industry
CEO
Simon Michel
Website
Headquarters
Burgdorf
Founded
2003
ISIN
CH0019396990
FIGI
BBG000Q8VLP5
Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. It operates through the following segments: Ypsomed Diabetes Care, Ypsomed Delivery Systems, and Others. The Ypsomed Diabetes Care segment is involved in the products that are sold directly to hospitals, doctors, pharmacies, and patients via Ypsomed subsidiaries and distributors. The Ypsomed Delivery Systems segment focuses on the pharmaceutical and biotech customers with injection systems and related services. The Others segment consists of Ypsotec and properties not used for operational purposes. The company was founded by Wilhelm Michel on December 29, 2003, and is headquartered in Burgdorf, Switzerland.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange YPSOMED HLDG SF 14,15 stocks are traded under the ticker OWX.
We've gathered analysts' opinions on YPSOMED HLDG SF 14,15 future price: according to them, OWX price has a max estimate of 525.12 EUR and a min estimate of 350.42 EUR. Watch OWX chart and read a more detailed YPSOMED HLDG SF 14,15 stock forecast: see what analysts think of YPSOMED HLDG SF 14,15 and suggest that you do with its stocks.
Yes, you can track YPSOMED HLDG SF 14,15 financials in yearly and quarterly reports right on TradingView.
YPSOMED HLDG SF 14,15 is going to release the next earnings report on Nov 12, 2025. Keep track of upcoming events with our Earnings Calendar.
YPSOMED HLDG SF 14,15 revenue for the last half-year amounts to 443.67 M EUR, despite the estimated figure of 364.62 M EUR. In the next half-year revenue is expected to reach 384.93 M EUR.
OWX net income for the last half-year is 57.33 M EUR, while the previous report showed 34.55 M EUR of net income which accounts for 65.93% change. Track more YPSOMED HLDG SF 14,15 financial stats to get the full picture.
Yes, OWX dividends are paid annually. The last dividend per share was 2.35 EUR. As of today, Dividend Yield (TTM)% is 0.48%. Tracking YPSOMED HLDG SF 14,15 dividends might help you take more informed decisions.
YPSOMED HLDG SF 14,15 dividend yield was 0.65% in 2024, and payout ratio reached 34.31%. The year before the numbers were 0.55% and 34.83% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jul 4, 2025, the company has 2.64 K employees. See our rating of the largest employees — is YPSOMED HLDG SF 14,15 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. YPSOMED HLDG SF 14,15 EBITDA is 222.32 M EUR, and current EBITDA margin is 28.43%. See more stats in YPSOMED HLDG SF 14,15 financial statements.
Like other stocks, OWX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade YPSOMED HLDG SF 14,15 stock right from TradingView charts — choose your broker and connect to your account.